CA3045902C - Anticorps monoclonaux humains specifiques a la flt3 et leur utilisation - Google Patents

Anticorps monoclonaux humains specifiques a la flt3 et leur utilisation

Info

Publication number
CA3045902C
CA3045902C CA3045902A CA3045902A CA3045902C CA 3045902 C CA3045902 C CA 3045902C CA 3045902 A CA3045902 A CA 3045902A CA 3045902 A CA3045902 A CA 3045902A CA 3045902 C CA3045902 C CA 3045902C
Authority
CA
Canada
Prior art keywords
antibody
seq
antigen
flt3
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3045902A
Other languages
English (en)
Other versions
CA3045902A1 (fr
Inventor
Dimiter S. Dimitrov
Weizao Chen
Terry J. Fry
Christopher Chien
Haiying Qin
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Priority claimed from PCT/US2017/067974 external-priority patent/WO2018119279A1/fr
Publication of CA3045902A1 publication Critical patent/CA3045902A1/fr
Application granted granted Critical
Publication of CA3045902C publication Critical patent/CA3045902C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

L'invention concerne des anticorps monoclonaux humains qui se lient de manière spécifique à la tyrosine kinase 3 de type Fms (FLT3). L'invention concerne également des récepteurs d'antigènes chimériques (CAR) et d'autres conjugués d'anticorps qui comprennent les anticorps monoclonaux spécifiques à la FLT3. L'invention concerne en outre des procédés de diagnostic et de traitement du cancer associé à FLT3, tels que la leucémie lymphoblastique aiguë (ALL) ou la leucémie myéloïde aiguë (AML).
CA3045902A 2016-12-21 2017-12-21 Anticorps monoclonaux humains specifiques a la flt3 et leur utilisation Active CA3045902C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662437547P 2016-12-21 2016-12-21
US62/437,547 2016-12-21
PCT/US2017/067974 WO2018119279A1 (fr) 2016-12-21 2017-12-21 Anticorps monoclonaux humains spécifiques à la flt3 et leur utilisation

Publications (2)

Publication Number Publication Date
CA3045902A1 CA3045902A1 (fr) 2018-06-28
CA3045902C true CA3045902C (fr) 2025-11-25

Family

ID=

Similar Documents

Publication Publication Date Title
US12012455B2 (en) Human monoclonal antibodies specific for FLT3 and uses thereof
US11939377B2 (en) Affinity matured CD22-specific monoclonal antibody and uses thereof
AU2020206308B2 (en) Cross-species single domain antibodies targeting mesothelin for treating solid tumors
US11078286B2 (en) Monoclonal antibodies specific for fibroblast growth factor receptor 4 (FGFR4) and methods of their use
US11066479B2 (en) Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof
AU2020212534B2 (en) High affinity monoclonal antibodies targeting glypican-1 and methods of use
WO2017196847A1 (fr) Anticorps anti-nouveau récepteur variable d'antigène (vnar) et conjugués d'anticorps ciblant des antigènes tumoraux et viraux
AU2018268970B2 (en) Human monoclonal antibody targeting tnfr2 for cancer immunotherapy
WO2017214182A1 (fr) Anticorps entièrement humain ciblant pdi pour l'immunothérapie anticancéreuse
CA3066953A1 (fr) Anticorps monoclonaux humains specifiques de cd33 et leurs procedes d'utilisation
CA3045902C (fr) Anticorps monoclonaux humains specifiques a la flt3 et leur utilisation